<DOC>
	<DOCNO>NCT02833155</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerance entinostat administer orally single agent weekly dosing schedule . Additionally , study characterize pharmacokinetics parameter Chinese postmenopausal woman advance breast cancer . And define profile adverse event , include laboratory parameter subject</brief_summary>
	<brief_title>Entinostat Chinese Postmenopausal Women Patients With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Entinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>For inclusion study patient fulfil follow criterion : Provision inform consent prior study specific procedure . Postmenopausal woman age ≤ 65years . Estrogen receptor ( ER ) / progesterone receptor ( PR ) positive breast cancer confirm pathology . Once receive nonsteroidal aromatase inhibitor ( letrozole / anastrozole ) treatment , disease recurrence progression breast cancer currently . Patients must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 . And recently ( past 2 month ) , weight loss 10 % average weight . Patients must life expectancy &gt; 3 month . Patients must adequate organ bone marrow function define follow laboratory result . 1 . .absolute neutrophil count ( ANC ) ≥ 1,500 /mm3 2. . Platelets≥100,000 /mm3 3. . White blood cell count ( WBC） ≥ 3,000 /mm3 4. . Hemoglobin ≥ 9 g/dL . 5. . Creatinine ≤ 1.5 time upper limit normal ( ULN ) institution Creatinine clearance ≥ 60 ml/min/1.73m2 6. . Total bilirubin ≤ 1.5 time upper limit normal institution ( ULN ) 7 . .Aspartate transaminase ( AST/SGOT ) alanine transaminase ( ALT/SGPT ) ≤ 2.5 time upper limit . Patients must able take drug n't spit , malabsorption problem . Able comply study procedure followup examination . Patients known central nervous system metastasis except patient terminate steroid treatment brain metastasis spinal cord compression remain disease stable least 1 month . Previous treatment entinostat histone deacetylase inhibitor ( Valproic acid , Chidamide etc ) . Known allergy ingredient entinostat drug class . Women pregnant breastfeeding ( premenopausal ) . For woman childbearing potential , agreement use medically approve contraception measure ( intrauterine device ( IUD ) , birth control pill condom ) continue use duration study treatment 3 month last dose study treatment . Had receive chemotherapy/radiotherapy anticancer therapy study within 4 week start study treatment . Patients must completely recovered adverse event due previous agent administer 4 week ( except alopecia ) . Major surgery within 28 day start study treatment . Patients serious uncontrolled systemic disease ( severe liver dysfunction , severe renal dysfunction , poorly control diabetes , poorly control acute infection ) . Unstable decompensated respiratory cardiovascular disease , peripheral vascular disease ( include diabetic vascular disease ) , organ transplantation . Received potent CYP1A2 CYP3A4 inducer and/or inhibitor ( include limit following drug : ketoconazole , rifampicin , atazanavir , Clarithromycin , indinavir , itraconazole , nelfinavir , saquinavir , telithromycin , voriconazole , grapefruit grapefruit juice , rifabutin , phenytoin , Carbamazepine phenobarbital ) . Patients another active cancer ( exclude basal cell carcinoma cervical intraepithelial neoplasia [ cervical intraepithelial neoplasia （CIN）/cervical carcinoma situ ] melanoma insitu ) . Prior history cancer allow , long active disease within prior 5 year . Active bleed new thrombotic disease use anticoagulant drug , patient bleed tendency . Meet follow criterion cardiac parameter : correct QT interval ( QTc ) &gt; 470 msec rest condition . myocardial infarction arterial thrombosis event within 6 month , experience severe unstable angina , New York Heart Association ( NYHA ) Class III IV disease . Resting ECG imply clinically significant abnormal rhythm , conduction morphology , example , leave bundle branch block , third degree heart block , second degree heart block , PR interval &gt; 250 msec . Any factor ( , heart failure , hypokalemia , inherit long QT syndrome , acquire long QT syndrome family history unexplained sudden death immediate family member 40 year old ) know combine drug ( , sotalol , cisapride , clozapine , amiodarone erythromycin , etc . ) increase risk prolongation QTc interval arrhythmic event . History known human immunodeficiency virus ( HIV ) infection Known drug longterm alcoholic . Patient currently enrol ( complete within 30 day study drug administration ) another investigational drug study . Involvement plan conduct study . Possible low inclusion criterion accord researcher ( weak , etc ) , suitable study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>entinostat</keyword>
	<keyword>breast cancer</keyword>
</DOC>